


Osilodrostat

Chemical Properties

CAS No. : 928134-65-0
Formula: C₁₃H₁₀FN₃
Molecular Weight: 227.24
Appearance: no data available
Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Osilodrostat (LCI699) (LCI699) is an effective inhibitor of human 11 β -hydroxylase (IC ₅₀ : 2.5 nM) and aldosterone synthase (IC ₅₀ : 0.7 nM).
Targets(IC ₅₀)	Glucocorticoid Receptor,Others,Hydroxylase
In vivo	Osilodrostat and pasireotide monotherapies can significantly affect in the histology and mean weights of the pituitary and adrenal glands, liver, and ovary/oviduct. Osilodrostat is associated with adrenocortical hypertrophy and hepatocellular hypertrophy. The combination of Osilodrostat with pasireotide ameliorates the liver and adrenal gland changes observed with monotherapy and does not exacerbate any target organ changes. C _{max} and AUC(0-24h) of Osilodrostat and pasireotide increase in an approximately dose-proportional manner. Osilodrostat treatment reduces urinary free cortisol in patients with Cushing's disease; 78.9% has normal urinary free cortisol at week 22.
Animal Research	Sixty male and 60 female rats are randomized into single-sex groups to receive daily doses of pasireotide (0.3 mg/kg/day, s.c.), osilodrostat (20 mg/kg/day, p.o.), osilodrostat/pasireotide in combination (low dose, 1.5/0.03 mg/kg/day; mid-dose, 5/0.1 mg/kg/day; or high dose, 20/0.3 mg/kg/day), or vehicle for 13 weeks.

Solubility Information

Solubility	DMSO: 50 mg/mL (220.03 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.4006 mL	22.0032 mL	44.0063 mL
5 mM	0.8801 mL	4.4006 mL	8.8013 mL
10 mM	0.4401 mL	2.2003 mL	4.4006 mL
50 mM	0.088 mL	0.4401 mL	0.8801 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Li L, et al. Osilodrostat (LCI699), a potent 11 β -hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicol Appl Pharmacol. 2015

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481